Total revenue for Q4 2025 reached $41.3 million, significantly up from $15.0 million in Q4 2024, primarily driven by increased collaboration revenue from agreements with GSK and Pfizer. For the full year, total revenue was $66.8 million, compared to $48.0 million in 2024. The company attributed this revenue growth to successful collaborations and the advancement of its tebipenem HBr program, which is aimed at treating complicated urinary tract infections (cUTI).
Spero's CEO, Esther Rajavelu, highlighted the progress made in 2025, particularly the resubmission of the New Drug Application (NDA) for tebipenem HBr to the FDA, which is expected to address significant unmet medical needs. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 18, 2026, for this application. Rajavelu expressed optimism about the potential of tebipenem HBr to improve treatment options for patients with cUTI, emphasizing the importance of GSK's partnership in advancing this program.
As of December 31, 2025, Spero had cash and cash equivalents of $40.3 million, which the company estimates will be sufficient to fund operations into 2028. This financial stability positions Spero well as it continues to execute its business strategy and explore opportunities to expand its portfolio of clinical-stage product candidates. The company remains focused on fulfilling its obligations under its licensing agreement with GSK while advancing other corporate activities.
